Combination chemotherapy with paclitaxel, ifoseamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy: Advanced report

被引：0
|
作者：
不详
机构：
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2006年 / 5卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：291 / 291
页数：1
相关论文
共 50 条
  • [21] Treatment of Patients With Metastatic Urothelial Cancer "Unfit" for Cisplatin-Based Chemotherapy
    Galsky, Matthew D.
    Hahn, Noah M.
    Rosenberg, Jonathan
    Sonpavde, Guru
    Hutson, Thomas
    Oh, William K.
    Dreicer, Robert
    Vogelzang, Nicholas
    Sternberg, Cora N.
    Bajorin, Dean F.
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) : 2432 - 2438
  • [22] ELIGIBILITY OF PATIENTS WITH UROTHELIAL CANCER OF THE BLADDER FOR NEOADJUVANT CISPLATIN-BASED CHEMOTHERAPY
    Vemana, Goutham
    Sandhu, Gurdarshan
    Nepple, Kenneth
    Strope, Seth
    JOURNAL OF UROLOGY, 2013, 189 (04): : E54 - E54
  • [23] THE EFFICIENCY OF SECOND-LINE CHEMOTHERAPY WITH GEMCITABINE AND PACLITAXEL FOR ADVANCED UROTHELIAL CARCINOMA RESISTANT TO CISPLATIN-BASED CHEMOTHERAPY
    Nishihara, Chikako
    Kuratsukuri, Katsuyuki
    Iguchi, Taro
    Tamada, Satoshi
    Tanaka, Tomoaki
    Uchida, Junji
    Kawashima, Hidenori
    Nakatani, Tatsuya
    JOURNAL OF UROLOGY, 2013, 189 (04): : E765 - E765
  • [24] Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy
    Fujii, Hironori
    Iihara, Hirotoshi
    Kajikawa, Noriko
    Kobayashi, Ryo
    Suzuki, Akio
    Tanaka, Yoshihiro
    Yamaguchi, Kazuya
    Yoshida, Kazuhiro
    Itoh, Yoshinori
    ANTICANCER RESEARCH, 2017, 37 (12) : 6831 - 6837
  • [25] Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy
    Kobayashi, Keita
    Matsuyama, Hideyasu
    Shimizu, Kosuke
    Fujii, Nakanori
    Inoue, Ryo
    Yamamoto, Yoshiaki
    Matsumoto, Hiroaki
    Nagao, Kazuhiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (08) : 775 - 780
  • [26] Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy
    Galsky, Matthew D.
    Moshier, Erin
    Krege, Susan
    Lin, Chia-Chi
    Hahn, Noah
    Ecke, Thorsten
    Sonpavde, Guru
    Godbold, James
    Oh, William K.
    Bamias, Aristotle
    CANCER, 2013, 119 (16) : 3012 - 3019
  • [27] Factors that Predict Neutropenia in Korean Patients with Advanced Urothelial Cancer after Cisplatin-Based Systemic Chemotherapy
    Kwon, Whi-An
    Oh, Tae Hoon
    Lee, Jea Whan
    Seo, Ill Young
    Park, Seung Chol
    UROLOGY JOURNAL, 2018, 15 (04) : 168 - 172
  • [28] Efficacy and tolerability of Paclitaxel-Gemcitabine therapy for urothelial carcinoma in patients who have received prior platinum-based chemotherapy.
    Tomisaki, Ikko
    Minato, Akinori
    Fujimoto, Naohiro
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [29] Gemcitabine-Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy
    Koguchi, Dai
    Matsumoto, Kazumasa
    Ikeda, Masaomi
    Shimizu, Yuriko
    Nakamura, Marie
    Shiono, Yutaka
    Katsumata, Hiroki
    Sato, Yuichi
    Iwamura, Masatsugu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (20)
  • [30] A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy
    Galsky, Matthew D.
    Hahn, Noah M.
    Rosenberg, Jonathan
    Sonpavde, Guru
    Hutson, Thomas
    Oh, William K.
    Dreicer, Robert
    Vogelzang, Nicholas
    Sternberg, Cora
    Bajorin, Dean F.
    Bellmunt, Joaquim
    LANCET ONCOLOGY, 2011, 12 (03): : 211 - 214
12345